Viewing Study NCT04848558


Ignite Creation Date: 2025-12-25 @ 12:17 AM
Ignite Modification Date: 2025-12-25 @ 10:19 PM
Study NCT ID: NCT04848558
Status: COMPLETED
Last Update Posted: 2023-07-03
First Post: 2021-04-14
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of Nipocalimab in Healthy Male and Female Participants
Sponsor: Janssen Research & Development, LLC
Organization:

Study Overview

Official Title: A Phase 1 Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nipocalimab in Healthy Male and Female Participants
Status: COMPLETED
Status Verified Date: 2023-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of nipocalimab following subcutaneous (SC) administration compared with intravenous (IV) administration in healthy participants.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2020-005892-10 EUDRACT_NUMBER None View
80202135EDI1001 OTHER Janssen Research & Development, LLC View